The effect of dopamine on MPTP-induced rotarod disability

Neuroscience Letters

Volumn 543, Issue , 2013, Pages 105-109

  Ayton, Scott ^a   George, Jessica L ^a   Adlard, Paul A ^a   Bush, Ashley I ^a   Cherny, Robert A ^a   Finkelstein, David I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Dopamine; MPTP; Parkinson's disease; Rotarod

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; LEVODOPA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISABILITY; DRUG INTOXICATION; MOUSE; NONHUMAN; PERFORMANCE; PHYSIOLOGIC MONITORING; PRIORITY JOURNAL; ROTAROD TEST; SUPPLEMENTATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BENZAZEPINES; DOPAMINE; DOPAMINE AGENTS; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; RECEPTORS, DOPAMINE D1; ROTAROD PERFORMANCE TEST; TIME FACTORS;

EID: 84877124096     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.02.066     Document Type: Article

References (25)

1. Antzoulatos E., Jakowec M.W., Petzinger G.M., Wood R.I. Sex differences in motor behavior in the mptp mouse model of Parkinson's disease. Pharmacol. Biochem. Behav. 2010, 95(4):466-472.
2. Ara J., Przedborski S., Naini A.B., Jackson-Lewis V., Trifiletti R.R., Horwitz J., Ischiropoulos H. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc. Natl. Acad. Sci. U. S. A. 1998, 95(13):7659-7663.
3. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., Bioulac B.H., Gross C.E., Fisone G., Bloch B., Bezard E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57(1):17-26.
4. Bezard E., Dovero S., Imbert C., Boraud T., Gross C.E. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse (New York, NY) 2000, 38(3):363-368.
5. Burch D., Sheerin F. Parkinson's disease. Lancet 2005, 365(9459):622-627.
6. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 1983, 80(14):4546-4550.
7. Cenci M.A. Dopamine dysregulation of movement control in l-Dopa-induced dyskinesia. Trends Neurosci. 2007, 30(5):236-243.
8. Chalmers J.P., Baldessarini R.J., Wurtman R.J. Effects of l-Dopa on norepinephrine metabolism in the brain. Proc. Natl. Acad. Sci. U. S. A. 1971, 68(3):662-666.
9. Colotla V., Flores E., Oscos A., Meneses A., Tapia R. Effects of MPTP on locomotor activity in mice. Neurotoxicol. Teratol. 1990, 12:405.
10. Geng X., Song L., Pu X., Tu P. Neuroprotective effects of phenylethanoid glycosides from Cistanches salsa against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice. Biol. Pharm. Bull. 2004, 27(6):797-801.
11. Gorton L.M., Vuckovic M.G., Vertelkina N., Petzinger G.M., Jakowec M.W., Wood R.I. Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse. Behav. Brain Res. 2010, 213(2):253-262.
12. Hu X., Zhang D., Pang H., Caudle W.M., Li Y., Gao H., Liu Y., Qian L., Wilson B., Di Monte D.A., Ali S.F. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J. Immunol. 2008, 181(10):7194-7204.
13. Hung L.W., Villemagne V.L., Cheng L., Sherratt N.A., Ayton S., White A.R., Crouch P.J., Lim S., Leong S.L., Wilkins S., George J. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. J. Exp. Med. 2012, 209(4):837-854.
14. Kawasaki T., Ago Y., Kitao T., Nashida T., Takagi A., Takuma K., Matsuda T. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology 2008, 55(5):654-660.
15. Lei P., Ayton S., Finkelstein D.I., Spoerri L., Ciccotosto G.D., Wright D.K., Wong B.X., Adlard P.A., Cherny R.A., Lam L.Q., Roberts B.R. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 2012, 18(2):291-295.
16. Matsushita N., Misu Y., Goshima Y. In vivo antagonism of the behavioral responses to l-3-,4-dihydroxyphenylalanine by l-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats. Eur. J. Pharmacol. 2009, 605(1-3):109-113.
17. Mohanasundari M., Srinivasan M.S., Sethupathy S., Sabesan M. Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice. J. Neurol. Sci. 2006, 249(2):140-144.
18. Neisewander J.L., Fuchs R.A., O'Dell L.E., Khroyan T.V. Effects of SCH-23390 on dopamine D1 receptor occupancy and locomotion produced by intraaccumbens cocaine infusion. Synapse (New York, NY) 1998, 30(2):194-204.
19. O'Callaghan J.P., Miller D.B., Reinhard J.F. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced damage of striatal dopaminergic fibers attenuates subsequent astrocyte response to MPTP. Neurosci. Lett. 1990, 117(1-2):228-233.
20. Rousselet E., Callebert J., Parain K., Joubert C., Hunot S., Hartmann A., Jacque C., Perez-Diaz F., Cohen-Salmon C., Launay J.M., Hirsch E.C. Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp. Neurol. 2002, 177(1):183-192.
21. Rozas G., Lopez-Martin E., Guerra M.J., Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of parkinsonism. J. Neurosci. Methods 1998, 83(2):165-175.
22. Sankar S.R., Manivasagam T., Krishnamurti A., Ramanathan M. The neuroprotective effect of withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical variables. Cell. Mol. Biol. Lett. 2007, 12(4):473-481.
23. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., Schwarting R.K. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav. Genet. 2000, 30(3):171-182.
24. Stanic D., Finkelstein D.I., Bourke D.W., Drago J., Horne M.K. Timecourse of striatal re-innervation following lesions of dopaminergic SNPC neurons of the rat. Eur. J. Neurosci. 2003, 18(5):1175-1188.
25. Wang P., Niu L., Gao L., Li W.X., Jia D., Wang X.L., Gao G.D. Neuroprotective effect of gypenosides against oxidative injury in the substantia nigra of a mouse model of Parkinson's disease. J. Int. Med. Res. 2010, 38(3):1084-1092.